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Abstract
Background: PAX2 is a transcription factor with an important role in embryogenic development.
However, PAX2 expression was frequently identified in neoplasia responsible for the growth and
survival of cancer cells. Due to alternative splicing of exon 6, exon 10 and exon 12 four isoforms
of PAX2 are described so far.
Methods: The expression of an intron 9 containing PAX2 splice variant was analyzed in neoplastic
B cell and solid tumor cell lines as well as in primary tumor samples by quantitative RT-PCR. PAX2
proteins were detected by Western Blot in a subset of cell lines.
Results: All 14 lymphoma cell lines expressed an undescribed PAX2 splice variant containing the
entire intron 9 sequence and the exon 10 sequence. This splice variant could also be detected in
35 solid tumor cell lines, in leukemia and lymphoma as well as in colon carcinoma and melanoma
patient samples and in blood samples of healthy donors. Expression of this new splice variant on
protein level was verified by Western Blot analysis.
Conclusion: We discovered a previously undescribed intron 9 and exon 10 containing splice
variant of PAX2 in B-cell neoplasia and in solid tumors on mRNA and protein level.
Background
The PAX gene family was first described in Drosophila and
later found to be conserved across species [1]. PAX gene
products function as transcription factors. They all share
the evolutionarily conserved 128 amino acid paired
domain at their N-terminal, which mediates attachment
to DNA sequences [2]. Nine PAX genes (PAX1–PAX9)
have so far been described in vertebrates; these proteins
are subdivided into four classes based on the presence of
conserved sequence motifs, the octapeptide (repression
domaine) and the homeodomaine (DNA binding
domaine) [3]. The PAX2 gene is located on the short arm
of chromosome 10, locus 24–25 [4] and encodes a tran-
scription factor that has a critical role in the development
of the urogenital tract, the eyes and ears, and the CNS [5].
It belongs to the subgroup 2, characterized by the
octapeptide sequence and a truncated homeodomaine [6]
and is composed of 12 exons spanning approximately 86
kb [5].
Although PAX2 is primarily expressed during embryonic
development and expression is normally repressed upon
terminal differentiation, PAX gene expression was fre-
quently identified in tumor cell lines, including lym-
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phoma, breast, ovarian, lung, and colon cancer, as well as
in primary tumor tissue samples [7] and was suggested as
a sensitive marker for renal neoplasms [8].
Apoptosis was induced in cell lines following RNA inter-
ference to silence PAX2 expression, suggesting that endog-
enous PAX2 gene expression is required for the growth
and survival of cancer cells [9,10,7]. Therefore, it has
gained interest as a target for immunotherapy [11].
Downstream targets of PAX2 are still less defined. PAX2
has been reported, to act as a transcriptional repressor of
p53 and a transcriptional activator of WT1 [12]. In breast
[13] and prostate cancers [14] as well as in acute myeloid
leukemia (AML) [15] a correlation with WT1 expression
has been observed, suggesting that PAX2 is a positive tran-
scriptional regulator of WT1. Recently, WNT5A [16] and
human beta-defensin-1 [17] were identified as PAX2 tar-
gets.
Four isoforms of PAX2 are described so far. They are prod-
ucts of alternative splicing of exon 6, exon 10 and exon 12:
Exon 6 is present in the PAX2a transcript and absent in the
PAX2b transcript [18]. Insertion of exon 10 in the exon 6
missing PAX2c transcript results in a different reading
frame, and a stop codon is produced by the last three
bases of exon 11 [19]. PAX2d arises from deletion of the
first 19 bp of exon 12 and is found with and without exon
6 (PAX2d+ex6 und PAX2dΔex6) [20].
Here we characterized a previously undescribed intron 9
and exon10 containing splice variant of PAX2 in neoplas-
tic B cell lines and solid tumor cell lines as well as in
tumor tissue.
Methods
Cells and Reagents
14 lymphoma cell lines (AMO-1, DG75, EHEB, KARPAS-
422, KM-H2, HDLM-2, L540, RAJI, SU-DHL-4, SUP-M2,
U698, U937, U266, BONNA-12) and 35 solid tumor cell
lines (4 thyroid cancer cell lines: 8505C, CGTHW-1,
BCPAP, TT260Co2; 7 renal cell carcinoma cell lines:
A706; Caki1; ACHN; A498; SN12; CC5; Caki2; 8
melanoma cell lines: SKMel23, Mel10, Mel16, Mel-HO,
SKMel24, SKMel5, Mel28, 624.28; 8 colon carcinoma cell
lines: SW620, HCT116, Cx94, CaCo2, Colo320, SW480,
Colo205, HBL 100, 5 breast cancer cell lines: Mx1, T47D,
MCF7, MDA-MB436, BT474; 3 lung carcinoma cell lines:
Column6, A427, DMS79) All human cell lines were pur-
chased from DSMZ (Braunschweig, Germany) and CLS
(Eppelheim, Germany). Cells were maintained in RPMI
1640 containing 10–20% FCS, 2% penicillin/streptomy-
cin and 2% glutamine (Gibco, Karlsruhe, Germany).
Patient samples
Fifteen primary low grade lymphoma, 9 myeloma, 11
acute lymphoblastic leukemia (ALL) samples and 7 AML
samples were taken from patients that underwent routine
diagnostics like venipuncture or bone marrow aspiration.
Primary tumor single cell suspensions were prepared by
ficoll hypaque separation. The lymphoma and leukemia
samples contained more than 80% of tumor cells; there-
fore no further separation was done. For multiple mye-
loma, CD138 positive cells were isolated using Mini
MACS technology (Miltenyi Biotec, Germany). Tumor
cells were resuspended in guanidium thiocyanate (GTC)
buffer and stored at -80°C. 12 melanoma (8 skin
melanoma, 4 ocular melanoma) and 12 colon carcinoma
tissue samples were obtained from patients that under-
went surgery for their tumors. Tissue samples were col-
lected and dissected under stringent sterile conditions to
prevent RNA contamination and immediately frozen in
liquid nitrogen. There were no specific inclusion criteria
with exception for the leukemia samples. Only PAX2
mRNA expressing AML and ALL samples were included.
All patients had given informed consent for the analysis.
Approval by the appropriate ethics committee has been
obtained (approval number EA4/090/08) and analyses
have therefore been performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki. Blood samples of healthy volunteers served as
negative controls.
RT-PCR
Total RNA was isolated by RNeasy Mini Kit including
RNase-Free DNase Set (Qiagen, Hilden, Germany).
Reverse transcription and quantitative Real Time RT-PCR
(LightCycler Technology, Roche Diagnostics) was done as
described elsewhere [15]. Primer sequences were designed
using the LightCycler Probe Design software, version 1.0
(LC, LightCycler; P, dephosphorylated; X, Fluorescein; Y,
LC Red 640): PBGD Forward: 5'-TGC AGG CTA CCA TCC
ATG TCC CTG C, Reverse: 5'-AGC TGC CGT GCA ACA
TCC AGG ATG G, LC probes: 5'-Y TGT GGG TCA TCC
TCA GGG CCA TCT TC P, 5'-CGT GGA ATG TTA CGA
GCA GTG ATG CCT ACC X, 187 bp. PAX2_1 Forward: 5'-
CTGGTCGTGACATGGC, Reverse: 5'-GGGTT-
GCACACAAGGG, LC probes: 5'-Y ACCCTGGCAGGAAT-
GGT P, 5'-GGGAAGCTACCCCACCT X, 185 bp; PAX2_2
Forward: 5'-GGTTACCCCCCTCACG, Reverse: 5'-
GGGACAGAATAGCAGTGG, LC probes: 5'-Y GGTGCCT-
GGTAGGTGACAA P, 5'-CCTCCACCCTGGCAGGA X, 212
bp.
PCR conditions and target-specific final MgCl2 concentra-
tions are listed in table 1. For each target an initial dena-
turation cycle at 95°C for 10 min, a final extension cycle
at 72°C for 2 min was performed. For quantification, PCR
products were cloned into the vector pCR2.1-TOPO (Inv-Journal of Translational Medicine 2009, 7:36 http://www.translational-medicine.com/content/7/1/36
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itrogen, Groningen, The Netherlands). A standard curve
with 3 dilutions of the appropriate plasmid in duplicates
was included in each PCR run. The specificity of the PCR
products was confirmed by melting curve analysis, by gel
electrophoresis using the AlphaEaseFC Imaging software
(Alpha Innotech, San Leandro, CA) and by sequencing.
Data analysis/statistical analysis
Analysis of RT-PCR expression data was done with the
LightCycler software (version 3). Sample concentrations
were calculated using the plasmid standard curve resulting
in marker concentrations. All samples were analysed in
duplicate. The average value of both duplicates was used
as a quantitative value. To correct for differences of cDNA
amount on a per-sample basis, results were provided as
ratio to housekeeping gene porphobilinogen deaminase
(PBGD) expression. Statistical significance was tested
using SPSS 15.0 software. For comparison of PAX2 intron
9 specific mRNA expression levels significance was esti-
mated by the 2-sided Mann-Whitney U test for compari-
son of two different groups.
Detection of PAX2 proteins by Western Blot
Western blots were performed on equal amounts of pro-
tein obtained by lysis of cells using MPer Protein Extrac-
tion Reagent (Pierce, Rockford, USA). The protein
concentration was measured by BCA method using BCA
Protein Reagent (Pierce, Rockford, USA). 50 μg protein
extract was loaded onto a 10% SDS-PAGE (Pierce, Rock-
ford, USA). Following electrophoreses, proteins were
transferred to nitrocellulose membranes, and then
blocked with 1%BSA in PBST (1× PBS, 0.1% Tween) over-
night at 4°C. Blots were then probed with rabbit anti-
PAX2 primary antibody (Zymed, San Francisco, USA) at
1:1000 dilution. After washing with PBST the membranes
were incubated with anti-rabbit IgG antibody conjugated
to horseradish peroxidase (HRP) at 1:5000 dilution
(Amersham, UK). Signal detection was visualized using
ECL chemiluminescence reagent (SuperSignal West Dura
Trial Kit, Pierce, Rockford, USA). As a control, blots were
probed with mouse anti-β-actin primary antibody
(1:2000, Sigma, Deisenkirchen, Germany) and HRP-con-
jugated anti-rabbit secondary antibody.
Results and discussion
Detection of a new splice variant in tumor cell lines and 
tissue by RT-PCR
RT-PCR analysis of the PAX2 transcript in 14 lymphoma
cell lines using a forward primer lying in exon 9 and a
reverse primer lying in exon 10 (primer set PAX2_1)
showed different PCR products on gel electrophoresis
(figure 1a):
All lymphoma cell lines showed a band of 339 bp of var-
ying intensity. A band of the expected size of 185 bp was
detected only in the cell lines KM-H2, EHEB, L540 and to
a lesser extent in the cell line DG75. Sequencing analysis
of the 339 bp PCR products revealed that this product
results from the insertion of the entire intron 9 sequence.
Thus, these cell lines expressed an undescribed PAX2
splice variant containing the entire intron 9 sequence and
the exon 10 sequence (figure 1b) with a stop codon at the
beginning of intron 9.
To analyze, whether the new splice variant is also
expressed in solid tumors, a panel of solid tumor cell lines
was tested by RT-PCR with the same primer set spanning
the intron 9 (PAX2_1). Analysis of the product size by gel
electrophoresis showed, that 7 of the 8 melanoma cell
lines, 7 of the 9 colon carcinoma cell lines and 1 of the 7
renal carcinoma cell lines expressed the intron 9 and exon
10 containing splice variant. The other cell lines showed
only a band of 185 bp. Additionally, 5 of 5 breast carci-
noma cell lines, 3 of 3 lung carcinoma cell lines and 4 of
4 thyroid carcinoma cell lines expressed this splice vari-
ant.
Next PAX2 positive leukemia patient samples were ana-
lyzed: In all 11 ALL samples and all 7 AML samples the
new splice variant could be detected on gel electrophore-
sis. Subsequently, samples from patients with low grade
lymphoma and multiple myeloma were analyzed. All 15
low grade lymphoma patient samples and 7 of the 9 mul-
tiple myeloma patient samples expressed the intron 9
containing splice variant. The remaining 2 multiple mye-
loma samples were negative for PAX2 mRNA (determined
by an RT-PCR assay detecting all splice variants of PAX2,
data not shown). However, 22 of 24 blood samples from
healthy donors surprisingly were also positive for the
intron 9 and exon 10 containing splice variant.
As PAX 2 recently gained importance as an immunothera-
peutic target [11], differences in the quantitative expres-
sion levels of this intron 9 positive PAX2 splice variant
Table 1: PCR conditions and specific MgCl2 concentrations for 
the amplification of PAX2 transcripts and the housekeeping 
gene PBGD.
PCR conditions
target MgCl2 (mmol/l) Cycles Temperature (°C) Time (s)
PBGD 4 45 95 0
65 12
72 10
PAX2_1 1,5 55 95 0
55 10
72 8
PAX2_2 2 55 95 0
57 12
72 10Journal of Translational Medicine 2009, 7:36 http://www.translational-medicine.com/content/7/1/36
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A: Agarose gel electrophoresis of the PAX2 exon 10 RT-PCR products from the mRNA of the lymphoma cell lines Figure 1
A: Agarose gel electrophoresis of the PAX2 exon 10 RT-PCR products from the mRNA of the lymphoma cell 
lines. All lymphoma cell lines: band of 339 bp of varying intensity. KM-H2, EHEB, L540 and DG75: band of the expected size of 
185 bp. Negative control: water instead of cDNA, positive control: plasmid (pCR2.1-TOPO) coding for the PAX2 exon 10 
PCR product. B: Schematic presentation of the sequencing result of the 339 bp PCR product: Detection of the new 
PAX2 splice variant containing the whole intron 9 sequence and exon 10 sequence C: Expression level of PAX2 intron 9 
specific mRNA: The relative amount was expressed as ratio marker [pg/μl]/PBGD [pg/μl]). The sample concentration was 
calculated using the plasmid standard curve. Thick bar: median expression level. D: Analysis of the expression of the dif-
ferent PAX2 splice variants by Western Blot: The known splice variants of 43–46 kDa and the new splice variant of 37 
kDa are exemplarily shown for the colon carcinoma cell line HCT116 and lymphoma cell line KM-H2.
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CCCCCCACTG GCCAGGGAAG CTACCCCACC TCCACCCTGG CAGGAATG GT
Intron 9
GCCTG g t a g g tgacaatgc tgcagctgcc taatctaggt ggggggaact
a aattgtggg tgagctgctg a  atggtctgt agtctgaggc tggggtgggg
ggagacacaa cgtcccctcc ctgcaaacca ctgctattct g  tccctctct
Exon 10 
c t c c t t a g AG GCTGCAGTTG GTCCCTCATC CTCCCTCATG AGCAAGCCGG
GGAGGAAGCT T GCAGAAGT GCCCCCTTGT GTGCAACCC  
Exon 9 
CTG GTCGTGA CATGGCGAGC ACCACTCTGC CTGGTTACCC CCCTCACG TG
CCCCCCACTG GCCAGGGAAG CTACCCCACC TCCACCCTGG CAGGAATG GT
Intron 9
GCCTG g t a g g tgacaatgc tgcagctgcc taatctaggt ggggggaact
a aattgtggg tgagctgctg a  atggtctgt agtctgaggc tggggtgggg
ggagacacaa cgtcccctcc ctgcaaacca ctgctattct g  tccctctct
Exon 10 
c t c c t t a g AG GCTGCAGTTG GTCCCTCATC CTCCCTCATG AGCAAGCCGG
GGAGGAAGCT T GCAGAAGT GCCCCCTTGT GTGCAACCC  
d
43 kDa
34 
42 kDa
PAX2
43 
kDa
42 kDa actin
55kDa
KM-H2         HCT116
1E-05
1E-04
1E-03
1E-02
1E-01
1E+00
1E+01
l
y
m
p
h
o
m
a
c
e
l
l
l
i
n
e
s
A
M
L
 
/
A
L
L
 
s
a
m
p
l
e
s
s
o
l
i
d
 
t
u
m
o
r
c
e
l
l
l
i
n
e
s
c
o
l
o
n
a
n
d
 
m
e
l
a
n
o
m
a
t
i
s
s
u
e
s
a
m
p
l
e
s
b
l
o
o
d
s
a
m
p
l
e
s
o
f
h
e
a
l
t
h
y
d
o
n
o
r
s
P
A
X
2
 
i
n
t
r
o
n
9
 
/
 
P
B
G
D
cJournal of Translational Medicine 2009, 7:36 http://www.translational-medicine.com/content/7/1/36
Page 5 of 6
(page number not for citation purposes)
between tumor cell lines and tissue compared to blood
samples from healthy donors were analyzed. A new RT-
PCR with intron 9 specific primers (primer set PAX2_2)
was established (figure 1c). In all 14 lymphoma cell lines
intron 9 specific mRNA could be detected, also in the cell
line KM-H2. The median expression level was 7.16 × 10-4
(range 1.42 × 10-4 - 7.61 × 10-2). Additionally, in all solid
tumor cell lines intron 9 specific mRNA was detected. The
median expression was 1.49 × 10-3 (7.96 × 10-5 - 1.04).
Moreover, the expression of the intron 9 positive PAX2
isoform was analyzed in 12 melanoma (8 skin melanoma,
4 ocular melanoma) and 12 colon carcinoma patient sam-
ples as well as in 9 AML and 5 ALL patients. All leukemia
samples, 11 of the 12 colon carcinoma and 7 of the 12
melanoma samples were positive for expression of intron
9 specific mRNA. The median expression level in solid
tumor samples was 1.17 × 10-1 (range 1.43 × 10-2 - 5.44)
and in leukemia samples 3.07 × 10-4 (range 1.22 × 10-5 -
1.3 × 10-2) (figure 1c). The expression level in solid tumor
tissue was 2 logs above the expression level of solid tumor
cell lines. The difference in PAX2 expression between solid
tumor cell lines and solid tumor samples may be due to
in-vitro selection in cell lines or stroma cell contribution
in tumor tissue.
However, the intron 9 specific mRNA was also found in
13 of 13 blood samples of healthy donors with a median
expression level of 1.18 × 10-2 (range 6.33 × 10-4 - 1.63 ×
10-1) (figure 1c). The median expression level was signifi-
cantly higher compared to solid tumor cell lines (p =
0.001) as well as lymphoma cell lines (p = 0.004) and
leukemia samples (p = 0.001). In contrast solid tumor tis-
sue samples exhibited a significant higher expression level
than healthy controls (p < 0.001). However, regarding
immunotherapeutic strategies we cannot exclude signifi-
cant expression of PAX2 intron 9 protein in peripheral
blood of healthy subjects and differences in mRNA
expression levels may not automatically lead to significant
differences in protein expression.
Detection of the new splice variant by Western Blot
To verify the expression of this intron 9 positive splice var-
iant on protein level, PAX2 protein expression was exam-
ined by Western Blot analysis in whole cell extracts of 3
colon carcinoma cell lines (HCT116, Colo320, Caco2)
and 4 lymphoma cell lines (SU-DHL-4, KARPAS-422,
U266, KM-H2). Protein bands corresponding to known
PAX2 isoforms (PAX2a 44.5 kDa, PAX2b 42 kDa, PAX2c
41.8 kDa, PAX2d 43.6 kDa, PAX2e 46.2 kDa) could be
found in all cell lines. Additionally, a band of approxi-
mately 37 kDa (figure 1d) was identified in all 4 lym-
phoma cell lines and in 2/3 colon carcinoma cell lines
(Caco2, HCT116), which corresponds to size of the new
intron 9 and exon 10 containing splice variant. Actin con-
trol staining revealed a band of the expected size of 42
kDa in both cell lines.
However, in blood samples of healthy volunteers bands
corresponding to the known splice variants of PAX2 and
to a lesser extent to the new splice variant could be also
detected. Expression of PAX2 in lymphoid cells was also
observed by others [8].
Therefore, regarding PAX2 targeted therapies like vaccina-
tion strategies caution is needed.
Conclusion
We found a previously undescribed intron 9 and exon 10
splice variant of PAX2 on mRNA and protein level in B cell
neoplasia and solid tumors as well as in peripheral blood
of healthy patients. This splice variant has a distinct and a
shorter C-terminus than the known exon 10 containing
splice variant PAX2c due to the deletion of the last 89
amino acid residues. Alternative processing represents an
important mechanism for the generation of various pro-
tein isoforms with different functions from one genetic
locus [21]. The function of this intron 9 containing splice
variant of PAX2 remains unclear, however, as the transac-
tivation of PAX2 relies on multiple COOH-terminal
domains [22], one might speculate, that the shortened
new splice variant has a reduced transactivation activity.
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